Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancer

被引：0
|
作者：
Hubbard, R.
Peintinger, F.
Liedtke, C.
Hatzis, C.
Kuerer, H. M.
Valero, V.
Buzdar, A. U.
Hortobagyi, G. N.
Pusztai, L.
Symmans, W. F.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Gen Hosp Loeben, Leoben, Austria
[3] Nuvera Biosci Inc, Woburn, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.544
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
544
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The prognostic value of histological grade determined after neoadjuvant chemotherapy of breast cancer
    Zombori, Tamas
    Ferenczi, Adam
    Sejben, Anita
    Almasi, Szintia
    Szelestei, Veronika
    Koszo, Renata
    Lantos, Tamas
    Kahan, Zsuzsanna
    Cserni, Gabor
    PATHOLOGY RESEARCH AND PRACTICE, 2025, 265
  • [32] Residual Disease After Neoadjuvant Chemotherapy for Breast Cancer
    Morris, Gloria J.
    Robinson, Patricia A.
    Lo, Shelly
    Samuel, Thomas A.
    Sheikh, Asad A.
    Jordan, W. Edward, III
    Thomas, Lisa C.
    Kiel, Krystyna
    Peters, Christopher A.
    SEMINARS IN ONCOLOGY, 2010, 37 (01) : 1 - 10
  • [33] Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy
    Vargas-Roig, Laura M.
    Cuello-Carrion, F. Dario
    Fernandez-Escobar, Nicolas
    Daguerre, Pedro
    Leuzzi, Marcela
    Ibarra, Jorge
    Gago, Francisco E.
    Nadin, Silvina B.
    Ciocca, Daniel R.
    MOLECULAR ONCOLOGY, 2008, 2 (01) : 102 - 111
  • [34] Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy
    Symmans, W. F.
    Wei, C.
    Gould, R.
    Zhang, Y.
    Hunt, K. K.
    Buchholz, T. A.
    Valero, V.
    Hortobagyi, G. N.
    Pusztai, L.
    Hatzis, C.
    CANCER RESEARCH, 2013, 73
  • [35] Prognostic Value of MRI Assessment of Residual Peritumoral Edema in Breast Cancer Treated With Neoadjuvant Chemotherapy
    Shigematsu, Hideo
    Fujimoto, Mutsumi
    Kobayashi, Yoshie
    Yasui, Daisuke
    Komoto, Daisuke
    Matsuura, Noriaki
    Kuraoka, Kazuya
    Yoshiyama, Tomoyuki
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2025, 61 (02) : 944 - 955
  • [36] Validation of the Residual Cancer Burden Index as a prognostic tool in women with locally advanced breast cancer treated with neoadjuvant chemotherapy
    Gomes da Cunha, Juliana Pierobon
    Goncalves, Rodrigo
    Silva, Fernando
    Aguiar, Fernando Nalesso
    Mota, Bruna Salani
    Chequim, Bruna Bello
    Soares, Jose Maria
    Baracat, Edmund C.
    Filassi, Jose Roberto
    JOURNAL OF CLINICAL PATHOLOGY, 2023, 76 (04) : 239 - 243
  • [37] Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy
    Jiang, Cui
    Wu, Shuo
    Jiang, Lei
    Gao, Zhichao
    Li, Xiaorui
    Duan, Yangyang
    Li, Na
    Sun, Tao
    PEERJ, 2019, 7
  • [38] Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
    Luen, S. J.
    Salgado, R.
    Dieci, M. V.
    Vingiani, A.
    Curigliano, G.
    Gould, R. E.
    Castaneda, C.
    D'Alfonso, T.
    Sanchez, J.
    Cheng, E.
    Andreopoulou, E.
    Castillo, M.
    Adams, S.
    Demaria, S.
    Symmans, W. F.
    Michiels, S.
    Loi, S.
    ANNALS OF ONCOLOGY, 2019, 30 (02) : 236 - 242
  • [39] Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor
    Basik, Mark
    Roseshter, Talia
    Klemantovich, Anna
    Cavallone, Luca
    Aguilar-Mahecha, Adriana
    Lafleur, Josiane
    Lan, Cathy
    Elebute, Oluwadara
    Jenna, Sarah
    Boileau, Jean-Francois
    Pelmus, Manuela
    CANCER RESEARCH, 2024, 84 (09)
  • [40] BREAST CANCER RESPONSE TO NEOADJUVANT CHEMOTHERAPY QUANTIFIED BY RESIDUAL CANCER BURDEN (RCB) SCORE
    Popa, Cristian Nicolae
    Birla, Rodica Daniela
    Dinu, Daniela Elena
    Iosif, Cristina
    Bogaseriu, Evelina
    Mates, Ioan Nicolae
    FARMACIA, 2022, 70 (04) : 712 - 719
12345